Videos

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.

Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance.

Paul E. Dato, MD, discusses how the presence of a BRCA mutation can influence treatment selection and sequencing, supporting consideration of upfront triplet therapy intensification and planning for earlier integration of PARP inhibitors when castration resistance develops.

Paul E. Dato, MD, discusses how formulation and dosing differences between abiraterone options affect absorption and tolerability, with the micronized version potentially providing better compliance due to no fasting requirement, though insurance coverage remains a significant hurdle for its use.

Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to alternative treatments.

An expert details key post-procedural recommendations following onabotulinumtoxinA injection for OAB.

Recent data suggest that obesity may be a risk factor for increased pain on transperineal biopsy.

An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.

"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.

A panelist discusses how the differences in prostate cancer among Black men are multifactorial, including biological differences in risk alleles, social determinants of health, and limited access to care and clinical trials.

A panelist discusses how Black men have a 67% higher incidence of prostate cancer and more than 2-fold higher risk of mortality compared with members of other races and ethnicities.

Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM.

Panelists discuss how evaluating a renal mass requires considering multiple factors, including patient expectations, comorbidities, life expectancy, tumor characteristics such as size and enhancement patterns, and predictive models to help guide decision-making.

Panelists discuss how cross-sectional imaging with pre- and postcontrast assessment remains the cornerstone of renal mass imaging, though newer software technologies now allow for better prediction of benign vs malignant tumors.

The study was published in JCO Oncology Practice.

Joshua M. Heiman, MD, details key findings from the POuND OUT study.

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.

Panelist discusses how the ability to administer treatments robotically, regardless of prostate size, affects resource expenditures in a clinic, highlighting the need for extended recovery periods and increased use of apps to streamline patient management and reduce resource burdens.

A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.

Amy E. Krambeck, MD, recaps her talk from AUA 2025.

John Michael DiBianco, MD, discusses findings from the BLUES trial.

The miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test.

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when added to hormone therapy while emphasizing that darolutamide may cause fewer central nervous system adverse effects like fatigue and cognitive changes, helping patients understand the potential benefits and tradeoffs to make a treatment decision that best fits their individual situation and preferences.

A panelist discusses how the outcomes of this study broadly align with real-world treatment patterns and clinical experiences, where enzalutamide and darolutamide both demonstrate efficacy in metastatic hormone-sensitive prostate cancer (mHSPC), although practical considerations such as darolutamide’s more favorable central nervous system (CNS) toxicity profile and enzalutamide’s longer clinical experience often influence prescribing decisions based on individual patient characteristics and comorbidities

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, with considerations for bioavailability, fasting requirements, and patient adherence.

Investigators found that benefits of treatments that are observed in trials also appear in the real world.

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial treatment including androgen deprivation therapy and abiraterone acetate.

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.